Literature DB >> 10738254

Detection of microsatellite alterations in the spectrum of melanocytic nevi in patients with or without individual or family history of melanoma.

S Birindelli1, G Tragni, C Bartoli, G N Ranzani, F Rilke, M A Pierotti, S Pilotti.   

Abstract

We studied a group of patients with or without individual or family history of melanoma for the occurrence of genetic alterations at microsatellite DNA sequences, usually referred to as microsatellite instability (MSI), and loss of heterozygosity (LOH). Microsatellite analysis of 3 markers located on chromosome 9p21-22 was performed for 88 melanocytic lesions, including 27 melanomas and 35 dysplastic and 26 common nevi, from 48 patients. Three additional markers, on 11q23, 17q21 and 5q22, were investigated in 16 melanomas. Overall, microsatellite alterations of the type usually considered low-level instability at 9p21-22 were observed in 22% of melanomas and 31% of dysplastic and 23% of common nevi. LOH at the same loci was found in 15% of melanomas and 8% of dysplastic nevi but never in common nevi. Cases with a positive family history of melanoma compared to those with a negative family history showed a higher microsatellite alteration frequency (43% vs. 20%), and the same was observed in melanoma compared to non-melanoma carriers (31% vs. 16%). Our results show that (i) MSI is common in all melanocytic lesions, though with differences in the group of patients which could have clinical relevance if confirmed, whereas LOH is restricted to melanomas and dysplastic nevi; (ii) various melanocytic lesions from the same patient represent clonally distinct tumors; (iii) the phenotype suggestive of DNA repair deficiency is influenced by a family or an individual history of melanoma; (iv) the microsatellite alteration frequency correlates with patient groups ordered according to increasing melanoma risk. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 10738254     DOI: 10.1002/(sici)1097-0215(20000415)86:2<255::aid-ijc16>3.0.co;2-l

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management.

Authors:  Keith Duffy; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2012-07       Impact factor: 11.527

Review 2.  Molecular aspects of melanocytic dysplastic nevi.

Authors:  Mahmoud Rezk Abd-Elwahed Hussein; Gary Stewart Wood
Journal:  J Mol Diagn       Date:  2002-05       Impact factor: 5.568

Review 3.  Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues.

Authors:  M R Hussein
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

Review 4.  [The dysplastic nevus. Separate entity, melanoma precursor or diagnostic dilemma?].

Authors:  A Roesch; M Landthaler; T Vogt
Journal:  Hautarzt       Date:  2003-09       Impact factor: 0.751

Review 5.  Genetic pathways to melanoma tumorigenesis.

Authors:  M R Hussein
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

6.  Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. The Melanoma Cooperative Group.

Authors:  G Palmieri; A Cossu; P A Ascierto; G Botti; M Strazzullo; A Lissia; M Colombino; M Casula; C Floris; F Tanda; M Pirastu; G Castello
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

Review 7.  Deficient mismatch repair: Read all about it (Review).

Authors:  Susan Richman
Journal:  Int J Oncol       Date:  2015-08-12       Impact factor: 5.650

Review 8.  Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers.

Authors:  Martina Amato; Renato Franco; Gaetano Facchini; Raffaele Addeo; Fortunato Ciardiello; Massimiliano Berretta; Giulia Vita; Alessandro Sgambato; Sandro Pignata; Michele Caraglia; Marina Accardo; Federica Zito Marino
Journal:  Int J Mol Sci       Date:  2022-08-05       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.